Amount Raised
$212 Million
Round Type
Post-IPO Equity
San DiegoBiotechnologyTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement for gross proceeds of approximately $212 million, before deducting placement agent fees and offering expenses.
Quick answer
Gossamer Bio raised $212 Million in a Post-IPO Equity round, dated July 20, 2023. Investors: Gossamer Bio Investor Relations, Dr. Jim White, Dr. Ardi Ghofrani, Dr. Ray Benza, Gossamer, Rock Springs Capital, Palo Alto Investors Lp and Federated Hermes Kaufmann Funds. Gossamer Bio is based in San Diego, California, United States.
- How much did Gossamer Bio raise?
- Gossamer Bio raised $212 Million in a Post-IPO Equity round on July 20, 2023.
- Who invested in Gossamer Bio?
- Gossamer Bio Investor Relations, Dr. Jim White, Dr. Ardi Ghofrani, Dr. Ray Benza, Gossamer, Rock Springs Capital, Palo Alto Investors Lp and Federated Hermes Kaufmann Funds are named as investors in this round.
- What does Gossamer Bio do?
- Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
- Where is Gossamer Bio based and how big is it?
- Gossamer Bio is based in San Diego, California, United States. Fundz records about 170 employees.
- Who are the decision-makers at Gossamer Bio?
- Fundz holds 1 contact at Gossamer Bio, including the Executive Officer, Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Gossamer Bio that raised within 45 days of this round, from Fundz verified event records.
- Oragenics raised $850K (Series C) on August 4, 2023.
- Foresee Pharmaceuticals raised $42M (Funding Round) on June 27, 2023.
- Entero Therapeutics raised $431K (Seed) on June 13, 2023.
- Alkeus Pharmaceuticals raised $150M (Series B) on June 5, 2023.
- Inhibrx raised $200M on August 31, 2023.
- Inhibrx raised $200M (Post-IPO Equity) on August 29, 2023.
Who to call at Gossamer Bio, and when
A new round usually means Gossamer Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Gossamer Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Gossamer Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Gossamer Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Gossamer Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Gossamer Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.